<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2403245069
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Diaglipt
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VILDAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        62.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of Diaglipt, vildagliptin, belongs to a<br />group of medicines called &ldquo;oral antidiabetics&rdquo;.<br />Diaglipt is used to treat adult patients with type 2 diabetes. It is<br />used when diabetes cannot be controlled by diet and exercise<br />alone. It helps to control the level of sugar in the blood. Your<br />doctor will prescribe Diaglipt either alone or together with<br />certain other antidiabetic medicines which you will already be<br />taking, if these have not proved sufficiently effective to control<br />diabetes.<br />Type 2 diabetes develops if the body does not make enough<br />insulin or if the insulin that the body makes does not work as<br />well as it should. It can also develop if the body produces too<br />much glucagon.<br />Insulin is a substance which helps to lower the level of sugar<br />in the blood, especially after meals. Glucagon is a substance<br />which triggers the production of sugar by the liver, causing the<br />blood sugar level to rise. The pancreas makes both of these<br />substances.<br />How Diaglipt works<br />Diaglipt works by making the pancreas produce more insulin<br />and less glucagon. This helps to control the blood sugar level.<br />This medicine has been shown to reduce blood sugar, which<br />may help to prevent complications from your diabetes. Even<br />though you are now starting a medicine for your diabetes, it is<br />important that you continue to follow the diet and/or exercise<br />which has been recommended for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Diaglipt 50 mg tablets:<br />- if you are allergic to vildagliptin or any of the other<br />ingredients of this medicine (listed in section 6). If you<br />think you may be allergic to vildagliptin or any of the other<br />ingredients of Diaglipt, do not take this medicine and talk to<br />your doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Diaglipt 50<br />mg tablets:<br />&bull; if you have type 1 diabetes (i.e. your body does not produce<br />insulin) or if you have a condition called diabetic ketoacidosis.<br />&bull; if you are taking an anti-diabetic medicine known as a<br />sulphonylurea (your doctor may want to reduce your dose of<br />the sulphonylurea when you take it together with Diaglipt in<br />order to avoid low blood glucose [hypoglycaemia]).<br />&bull; if you have moderate or severe kidney disease (you will<br />need to take a lower dose of Diaglipt).<br />&bull; if you are on dialysis.<br />&bull; if you have liver disease.<br />&bull; if you suffer from heart failure.<br />&bull; if you have or have had a disease of the pancreas.<br />If you have previously taken vildagliptin but had to stop taking<br />it because of liver disease, you should not take this medicine.<br />Diabetic skin lesions are a common complication of diabetes.<br />You are advised to follow the recommendations for skin and<br />foot care that you are given by your doctor or nurse. You are<br />also advised to pay particular attention to new onset of blisters<br />or ulcers while taking Diaglipt. Should these occur, you should<br />promptly consult your doctor.<br />A test to determine your liver function will be performed before<br />the start of Diaglipt treatment, at three-month intervals for the<br />first year and periodically thereafter. This is so that signs of<br />increased liver enzymes can be detected as early as possible.<br />Children and adolescents<br />The use of Diaglipt in children and adolescents up to 18 years<br />of age is not recommended.<br />Other medicines and Diaglipt 50 mg tablets<br />Tell your doctor or pharmacist if you are taking, have recently&nbsp;taken or might take any other medicines.<br />Your doctor may wish to alter your dose of Diaglipt if you are<br />taking other medicines such as:<br />- thiazides or other diuretics (also called water tablets)<br />- corticosteroids (generally used to treat inflammation)<br />- thyroid medicines<br />- certain medicines affecting the nervous system.<br />Pregnancy, breast-feeding and fertility.<br />If you are pregnant or breast-feeding, think you may be<br />pregnant or are planning to have a baby, ask your doctor or<br />pharmacist for advice before taking this medicine.<br />If you are pregnant or breast-feeding, think you may be<br />pregnant or are planning to have a baby, ask your doctor or<br />pharmacist for advice before taking this medicine.<br />You should not use Diaglipt during pregnancy. It is not known<br />if Diaglipt passes into breast milk. You should not use Diaglipt<br />if you are breast-feeding or plan to breast-feed.<br />Driving and using machines<br />If you feel dizzy while taking Diaglipt, do not drive or use<br />machines.<br />Diaglipt contains lactose<br />Diaglipt contains lactose. If you have been told by your doctor<br />that you have an intolerance to some sugars, contact your<br />doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as described in this leaflet<br />or as your doctor or pharmacist have told you. Check with<br />your doctor or pharmacist if you are not sure.<br />The amount of Diaglipt people have to take varies depending<br />on their condition. Your doctor will tell you exactly how many<br />tablets of Diaglipt to take. The maximum daily dose is 100 mg.<br />The usual dose of Diaglipt is either:<br />&bull; 50 mg daily taken as one dose in the morning if you are<br />taking Diaglipt with another medicine called a sulphonylurea.<br />&bull; 100 mg daily taken as 50 mg in the morning and 50 mg<br />in the evening if you are taking Diaglipt alone, with another<br />medicine called metformin or a glitazone, with a combination<br />of metformin and a sulphonylurea, or with insulin.<br />&bull; 50 mg daily in the morning if you have moderate or severe<br />kidney disease or if you are on dialysis.<br />Method of administration<br />Swallow the tablets whole with some water.<br />Duration of use<br />&bull; Take Diaglipt every day for as long as your doctor tells you.<br />You may have to take this treatment over a long period of<br />time.<br />&bull; Your doctor will regularly monitor your condition to check that<br />the treatment is having the desired effect.<br />If you take more Diaglipt 50 mg tablets than you should<br />If you take too many Diaglipt tablets, or if someone else has<br />taken your medicine, talk to your doctor straight away. Medical<br />attention may be needed. If you need to see a doctor or go to<br />the hospital, take the pack with you.<br />If you forget to take Diaglipt 50 mg tablets<br />If you forget to take a dose of this medicine, take it as soon as<br />you remember. Then take your next dose at the usual time. If<br />it is almost time for your next dose, skip the dose you missed.<br />Do not take a double dose to make up for a forgotten tablet.<br />If you stop taking Diaglipt 50 mg tablets<br />Do not stop taking Diaglipt unless your doctor tells you to. If<br />you have questions about how long to take this medicine, talk<br />to your doctor.<br />If you have any further questions on the use of this medicine,<br />ask your doctor, nurse, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects,<br />although not everybody gets them.<br />Some symptoms need immediate medical attention:<br />You should stop taking Diaglipt and see your doctor<br />immediately if you experience the following side effects:<br />&bull; Angioedema (rare: may affect up to 1 in 1,000 people):<br />Symptoms include swollen face, tongue or throat, difficulty<br />swallowing, difficulties breathing, sudden onset rash or hives,<br />which may indicate a reaction called &ldquo;angioedema&rdquo;.<br />&bull; Liver disease (hepatitis) (rare): Symptoms include yellow<br />skin and eyes, nausea, loss of appetite or dark-coloured urine,<br />which may indicate liver disease (hepatitis).<br />&bull; Inflammation of the pancreas (pancreatitis) (frequency not<br />known): Symptoms include severe and persistent pain in the<br />abdomen (stomach area), which might reach through to your<br />back, as well as nausea and vomiting.<br />Other side effects:<br />Some patients have had the following side effects while taking<br />Diaglipt and metformin:</p><p>&bull; Common (may affect up to 1 in 10 people): Trembling,<br />headache, dizziness, nausea, low blood glucose<br />&bull; Uncommon (may affect up to 1 in 100 people): Tiredness<br />Some patients have had the following side effects while taking<br />Diaglipt and a sulphonylurea:<br />&bull; Common: Trembling, headache, dizziness, weakness, low<br />blood glucose<br />&bull; Uncommon: Constipation<br />&bull; Very rare (may affect up to 1 in 10,000 people): Sore throat,<br />runny nose<br />Some patients have had the following side effects while taking<br />Diaglipt and a glitazone:<br />&bull; Common: Weight increase, swollen hands, ankle or feet<br />(oedema)<br />&bull; Uncommon: Headache, weakness, low blood glucose<br />Some patients have had the following side effects while taking<br />Diaglipt alone:<br />&bull; Common: Dizziness<br />&bull; Uncommon: Headache, constipation, swollen hands, ankle<br />or feet (oedema), joint pain, low blood glucose<br />&bull; Very rare: Sore throat, runny nose, fever<br />Some patients have had the following side effects while taking<br />Diaglipt, metformin and a sulphonylurea:<br />&bull; Common: Dizziness, tremor, weakness, low blood glucose,<br />excessive sweating<br />Some patients have had the following side effects while taking<br />Diaglipt and insulin (with or without metformin):<br />&bull; Common: Headache, chills, nausea (feeling sick), low blood<br />glucose, heartburn<br />&bull; Uncommon: Diarrhoea, flatulence<br />Since this product has been marketed, the following side<br />effects have also been reported:<br />&bull; Frequency not known (cannot be estimated from the<br />available data): Itchy rash, inflammation of the pancreas,<br />localised peeling of skin or blisters, muscle pain<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, nurse, or<br />pharmacist. This includes any possible side effects not listed<br />in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated<br />on the carton and label after &ldquo;EXP&rdquo;. The expiry date refers to<br />the last day of that month.<br />&bull; Store below 30&deg; C.<br />&bull; Store in the original package in order to protect from<br />moisture.<br />&bull; Do not throw away any medicines via wastewater or<br />household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: vildagliptin<br />Each tablet contains 50 mg vildagliptin.<br />The other ingredients are: Microcrystalline Cellulose, Lactose<br />anhydrous, Sodium Starch Glycolate, and Magnesium<br />Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Diaglipt 50 mg tablets are white to off-White, round, flat face
bevel edge, uncoated tablet, plain on both sides.
Diaglipt 50 mg tablets is available in packs 56 tablets 4
blisters (14 tablets / blister).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Co Ltd (Avalon<br />Pharma)<br />P.O.Box 4180 Riyadh 11491<br />2nd Industrial City, Riyadh, Kingdom of Saudi Arabia<br />Tel: +966 (11) 2653948 -2653427<br />Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تنتمي المادة الفعالة لدياجلبت، فيلداغليبتين، إلى مجموعة من الأدوية تسمى<br />.&raquo; مضادات السكري الفموية &laquo;<br />يُستخدم دياجلبت لعلاج المرضى البالغين المصابين بداء السكري من النوع<br />2، ويتم استخدامه عندما لا يمكن السيطرة على داء السكري عن طريق اتباع<br />نظام غذائي وممارسة الرياضة فقط؛ فهو يساعد على التحكم في مستوى<br />السكر في الدم. سيصف لك طبيبك دواء دياجلبت إما بمفرده أو مع بعض<br />الأدوية الأخرى المضادة للسكري التي ستتناولها بالفعل، إذا لم تثبت فعاليتها<br />بشكل كافٍ للسيطرة على داء السكري.<br />تظهر الإصابة بداء السكري من النوع 2 إذا كان الجسم لا ينتج كمية كافية<br />من الأنسولين أو إذا كان الأنسولين الذي يصنعه الجسم لا يعمل كما ينبغي.<br />يمكن أن يتطور أيضًا إذا كان الجسم ينتج الكثير من الغلوكاجون.<br />الأنسولين هي مادة تساعد على خفض مستوى السكر في الدم، وخاصة بعد<br />وجبات الطعام. الغلوكاجون هي مادة تؤدي إلى إنتاج السكر عن طريق<br />الكبد، مما يؤدي إلى ارتفاع مستوى السكر في الدم. يصنع البنكرياس هاتين<br />المادتين.<br />كيفية عمل دياجلبت<br />يعمل دياجلبت عن طريق جعل البنكرياس ينتج المزيد من الأنسولين ويقلل<br />من نسبة الغلوكاجون؛ هذا يساعد على التحكم في مستوى السكر في الدم.<br />وقد ثبت أن هذا الدواء يقلل من نسبة السكر في الدم، مما قد يساعد على منع<br />المضاعفات الناجمة عن داء السكري الخاص بك. على الرغم من أنك بدأت<br />الآن بتناول دواء لمعالجة داء السكري الخاص بك، من المهم أن تستمر في<br />اتباع النظام الغذائي و / أو ممارسة الرياضة التي تم التوصية بها لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أقراص دياجلبت 50 ملغ:<br />- إذا كنت لديك حساسية تجاه فيلداغليبتين أو أيٍّ من المكونات الأخرى لهذا<br />الدواء )المُدرجة في القسم 6(. إذا كنت تعتقد أنك قد تكون مصابًا بالحساسية<br />تجاه فيلداغليبتين أو أيٍّ من المكونات الأخرى لدياجلبت، لا تتناول هذا الدواء<br />وتحدث إلى طبيبك.<br />تحذيرات واحتياطات<br />استشِر طبيبك أو الصيدلي قبل أن تتناول أقراص دياجلبت 50 ملغ:<br />&bull; إذا كنت مصابًا بداء السكري من النوع 1 )أي أن جسمك لا يُنتج<br />الأنسولين( أو إذا كنت تعاني من حالة تسمى الحماض الكيتوني السكري.<br />&bull; إذا كنت تتناول دواءً مضادًا للسكري يُعرف باسم سلفونيليوريا )قد يرغب<br />طبيبك في تقليل جرعتك من سلفونيليوريا عند تناوله مع دياجلبت من أجل<br />تجنب انخفاض نسبة الجلوكوز في الدم ]نقص سكر الدم[(.<br />&bull; إذا كنت تعاني من أمراض الكلى المعتدلة أو الشديدة )ستحتاج إلى تناول<br />جرعة أقل من دياجلبت(.<br />&bull; إذا كنت تخضع لغسيل الكلى.<br />&bull; إذا كنت تعاني من أمراض الكبد.<br />&bull; إذا كنت تعاني من قصور في القلب.<br />&bull; إذا كنت تعاني من مرض بالبنكرياس.<br />إذا كنت قد تناولت فيلداغليبتين سابقًا ولكنك كنت مُضطر إلى التوقف عن<br />تناوله بسبب مرض الكبد، فلا يجب عليك تناول هذا الدواء.<br />تُعدُّ الآفات الجلدية لمرضى السكري من المضاعفات الشائعة لداء السكري.<br />يُنصح باتباع التوصيات الخاصة بالعناية بالبشرة والقدم التي يُقدِّمها لك طبيبك<br />أو ممرضتك. كذلك يُنصح بالانتباه في حالة ظهور البثور أو القرح الجديدة<br />أثناء تناول دياجلبت. في حالة حدوث ذلك يجب عليك استشارة طبيبك على<br />الفور.<br />سيتم إجراء اختبار لتحديد وظائف الكبد قبل بدء العلاج بدياجلبت، وذلك<br />كل ثلاثة أشهر للسنة الأولى وبشكل دوري بعد ذلك. سيتم ذلك بحيث يمكن<br />الكشف عن علامات زيادة إنزيمات الكبد في أقرب وقت ممكن.<br />الأطفال والمراهقون<br />لا يُنصح بإعطاء دياجلبت للأطفال والمراهقين دون 18 عامًا.<br />الأدوية الأخرى وأقراص دياجلبت 50 ملغ<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّ<br />أدوية أخرى.<br />قد يرغب طبيبك في تغيير جرعتك من دياجلبت إذا كنت تتناول أدوية أخرى<br />مثل:<br />- الثيازيدات أو مدرات البول الأخرى.</p><p>- الكورتيكوستيرويدات )تستخدم عادة لعلاج الالتهاب(.<br />- أدوية الغدة الدرقية.<br />- بعض الأدوية التي تؤثر على الجهاز العصبي.<br />الحمل والرضاعة الطبيعية والخصوبة<br />إذا كنتِ حاملً أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك حامل أو<br />تخططين لإنجاب طفل؛ استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />يجب عدم استخدام دياجلبت خلال فترة الحمل. ليس معروفًا ما إذا كان<br />دياجلبت ينتقل إلى حليب الأم. يجب عدم استخدام دياجلبت إذا كنتِ مُرضعة<br />أو تخططين للرضاعة الطبيعية.<br />القيادة واستخدام الآلات:<br />إذا شعرت بالدوار عند تناول دياجلبت، لا تقد السيارة أو تستخدم الآلات.<br />يحتوي دياجلبت على اللاكتوز:<br />يحتوي دياجلبت على اللاكتوز. إذا أخبرك طبيبك بأن جسمك لا يتحمل بعض<br />السكريات، يُرجى الاتصال بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائمًا على تناول هذا الدواء تمامًا كما هو موصوف في هذه النشرة أو<br />كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.<br />تختلف كمية دياجلبت الذي يتناولها الأفراد حسب حالتهم. سيخبرك طبيبك<br />بعدد أقراص دياجلبت التي يجب تناولها بالضبط. الجرعة اليومية القصوى<br />هي 100 ملغ.<br />الجرعة المعتادة من دياجلبت هي إما:<br />50 ملغ يوميًّا تؤخذ كجرعة واحدة في الصباح، إذا كنت تتناول دياجلبت &bull;<br />مع دواء آخر يسمى سلفونيليوريا.<br />100 ملغ يوميًّا تؤخذ 50 ملغ في الصباح و 50 ملغ في المساء، إذا كنت &bull;<br />تتناول دياجلبت بمفرده، أو مع دواء آخر يسمى ميتفورمين أو جليتازون، أو<br />مع مزيج من ميتفورمين وسلفونيليوريا، أو مع الأنسولين.<br />50 ملغ يوميًّا في الصباح إذا كنت تعاني من أمراض الكلى المتوسطة او &bull;<br />الشديدة، أو إذا كنت تخضع لغسيل الكلى.<br />طريقة تناول الدواء<br />ابتلع الأقراص كاملة مع القليل من الماء.<br />مدة الاستخدام<br />&bull; تناول دياجلبت كل يوم طوال فترة العلاج بحسب ما اخبرك طبيبك. قد<br />تضطر إلى تناول هذا العلاج لفترة طويلة.<br />&bull; سيرصد طبيبك حالتك بانتظام للتأكد من أن العلاج يحقق التأثير المطلوب.<br />إذا تناولت أقراص دياجلبت 50 ملغ أكثر مما يجب<br />إذا تناولت كمية كبيرة من أقراص دياجلبت، أو إذا تناول شخص آخر<br />دواءك؛ تحدث إلى طبيبك على الفور. قد تحتاج إلى الرعاية الطبية. إذا كنت<br />بحاجة إلى زيارة طبيب أو الذهاب إلى المستشفى خذ العبوة معك.<br />إذا نسيت تناول أقراص دياجلبت 50 ملغ<br />إذا نسيت تناول جرعة من هذا الدواء؛ تناولها حالما تتذكرها، ثم تناول<br />جرعتك التالية في الوقت المعتاد. إذا اقترب وقت تناول الجرعة التالية؛<br />تجاوز الجرعة التي فاتتك. لا تتناول جرعة مضاعفة لتعويض القرص<br />المنسي.<br />إذا توقفت عن تناول أقراص دياجلبت 50 ملغ<br />لا تتوقف عن تناول دياجلبت إلا إذا أخبرك طبيبك بذلك. إذا كانت لديك أسئلة<br />حول مدة تناول هذا الدواء تحدث إلى طبيبك.<br />إذا كانت لديك أيُّ أسئلة أخرى بخصوص استخدام الدواء، استشِر طبيبك أو<br />الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية قد يسبب هذا الدواء بعض الآثار الجانبية، على الرغم من<br />أن ذلك لا يحدث مع الجميع.<br />تحتاج بعض الأعراض إلى عناية طبية فورية<br />يجب عليك التوقف عن تناول دياجلبت ومراجعة طبيبك على الفور إذا كنت<br />تعاني من الآثار الجانبية التالية:<br />&bull; الوذمة الوعائية )نادرة: قد تصيب 1 من كل 1000 شخص(: تشمل<br />الأعراض )تورم الوجه أو اللسان أو الحلق، أو صعوبة في البلع، أو صعوبة<br />في التنفس، أو الطفح الجلدي المفاجئ أو الشرى(، مما قد يشير إلى رد فعل<br />.&raquo; الوذمة الوعائية &laquo; يسمى<br />&bull; أمراض الكبد )التهاب الكبد( )نادرة(: تشمل الأعراض )إصفرار الجلد<br />والعينين، أو الغثيان، أو فقدان الشهية، أو البول الداكن اللون(، مما قد يشير<br />إلى أمراض الكبد )التهاب الكبد(.<br />&bull; التهاب في البنكرياس )التهاب البنكرياس( )نسبة تكرار الحدوث غير<br />،&raquo; منطقة المعدة &laquo; معروفة(: تشمل الأعراض )ألمًا شديدًا ومستمرًا في البطن<br />والذي قد يصل إلى الظهر، بالإضافة إلى الغثيان والقيء(.<br />الأعراض الجانبية الأخرى:<br />عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول دياجلبت<br />وميتفورمين:<br />&bull; شائعة )قد تصيب 1 من كل 10 أشخاص(: الارتجاف، والصداع، والدوار،<br />والغثيان، وانخفاض جلوكوز الدم.<br />&bull; غير شائعة )قد تصيب 1 من كل 100 شخص(: التعب.<br />عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول دياجلبت<br />وسلفونيليوريا:</p><p>&bull; شائعة : الارتجاف، والصداع، والدوار، والضعف، وانخفاض جلوكوز<br />الدم.<br />&bull; غير شائعة : الإمساك.<br />&bull; نادرة جدًّا )قد تصيب 1 من كل 10000 شخص(: التهاب الحلق وسيلان<br />الأنف.<br />عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول دياجلبت<br />وجليتازون:<br />&bull; شائعة: زيادة الوزن، وتورم اليدين، أو الكاحل أو القدمين )وذمة(.<br />&bull; غير شائعة: الصداع، والضعف، وانخفاض جلوكوز الدم.<br />عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول دياجلبت بمفرده:<br />&bull; شائعة: الدوار.<br />&bull; غير شائعة: الصداع، الإمساك، وتورم اليدين، أو الكاحل أو القدمين<br />)وذمة(، وآلام المفاصل، وانخفاض جلوكوز الدم.<br />&bull; نادرة جدًّا: التهاب الحلق وسيلان الأنف والحمى.<br />عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول دياجلبت<br />وميتفورمين وسلفونيليوريا:<br />&bull; شائعة: الدوار، والرعشة، والضعف، وانخفاض جلوكوز الدم، والتعرُّق<br />الزائد.<br />عانى بعض المرضى من الآثار الجانبية التالية أثناء تناول دياجلبت<br />والأنسولين )مع أو بدون ميتفورمين(:<br />&bull; شائعة: الصداع، والقشعريرة، والغثيان )الشعور بالمرض(، وانخفاض<br />جلوكوز الدم، وحرقة المعدة.<br />&bull; غير شائعة: الإسهال وانتفاخ البطن.<br />منذ تسويق هذا المنتج تم أيضًا الإبلاغ عن الآثار الجانبية التالية:<br />نسبة التكرار غير معروفة )لا يمكن تقديرها من البيانات المتاحة(: طفح<br />جلدي مثير للحكة، والتهاب البنكرياس، وتقشير موضعي للجلد أو بثور،<br />وألم عضلي.<br />الإبلاغ عن الآثار الجانبية<br />إذا تعرضت لأيٍّ من الآثار الجانبية استشِر طبيبك أو الممرضة أو الصيدلي.<br />ويشمل هذا أيَّ آثار جانبية محتملة غير مُدرَجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.<br />&bull; يجب عدم استخدام الدواء بعد تاريخ انتهاء الصلاحية المُوضَّحة على<br />يشير تاريخ الانتهاء إلى اليوم الأخير من .EXP الكرتونة والعبوة بعد كلمة<br />ذلك الشهر.<br />&bull; يُحفظ في درجة حرارة أقل من 30 درجة مئوية.<br />&bull; يخزن في عبوته الأصلية. يحفظ بعيداً عن الرطوبة.<br />&bull; يجب عدم التخلُّص من أيِّ أدوية في مياه الصرف الصحي أو إلقائها في<br />القمامة. اسأل الصيدلي عن كيفية التخلُّص من الأدوية التي لم تَعُدْ بحاجة إلى<br />استخدامها؛ لأن هذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات دياجلبت 50 ملغ<br />المادة الفعالة: فيلدغليبتين<br />يحتوي كل قرص على 50 ملغ من فيلدغليبتين.<br />المكونات الأخرى هي: السليلوز الجريزوفولفين، واللاكتوز اللامائي، ونشا<br />الصوديوم جلايكولات، وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص دياجلبت 50 ملغ هي أقراص مستديرة بيضاء مائلة إلى الاصفرار<br />ذات حافة مشطوفة الوجه مُسطحة غير مطلية عادية على كلا الجانبين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الشرق الأوسط للصناعات الدوائية المحدودة. )أفالون فارما(<br />ص.ب. 4180 الرياض 11491<br />المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية<br />00 966 )11( 265 3948 &ndash; 265 هاتف 3427<br />00 966 )11( 265 فاكس 4723</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diaglipt 50mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 50 mg of vildagliptin.
Excipient with known effect: Each tablet contains 47.82 mg lactose (anhydrous).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
Diaglipt 50mg tablets are white to off-White, round, flat face bevel edge, uncoated tablet, plain on both sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:<br />As monotherapy<br />- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due<br />to contraindications or intolerance.<br />As dual oral therapy in combination with<br />- metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with<br />metformin,<br />- a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a<br />sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance,<br />- a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione<br />is appropriate.<br />As triple oral therapy in combination with<br />- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do<br />not provide adequate glycaemic control.<br />Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and<br />exercise plus a stable dose of insulin do not provide adequate glycaemic control.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in<br />combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the<br />recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one<br />dose of 50 mg in the evening.<br />2<br />When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. In this patient population, vildagliptin 100 mg daily was no more effective than vildagliptin 50 mg once daily.<br />When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.<br />Doses higher than 100 mg are not recommended.<br />If a dose of Diaglipt is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.<br />The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.<br />Additional information on special populations<br />Elderly (&ge; 65 years)<br />No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).</p><p>Renal impairment<br />No dose adjustment is required in patients with mild renal impairment (creatinine clearance &ge; 50 ml/min). In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of Diaglipt is 50 mg once daily (see also sections 4.4, 5.1 and 5.2).<br />Hepatic impairment<br />Diaglipt should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3x the upper limit of normal (ULN) (see also sections 4.4 and 5.2).<br />Paediatric population<br />Diaglipt is not recommended for use in children and adolescents (&lt; 18 years). The safety and efficacy of Diaglipt in children and adolescents (&lt; 18 years) have not been established. No data are available (see also section 5.1).<br />Method of administration<br />Oral use<br />Diaglipt can be administered with or without a meal (see also section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Diaglipt is not a substitute for insulin in insulin-requiring patients. Diaglipt should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.<br />Renal impairment<br />There is limited experience in patients with ESRD on haemodialysis. Therefore, Diaglipt should be used with caution in these patients (see also sections 4.2, 5.1 and 5.2).<br />3<br />Hepatic impairment<br />Diaglipt should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST &gt; 3x ULN (see also sections 4.2 and 5.2).<br />Liver enzyme monitoring<br />Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. Liver function tests should be performed prior to the initiation of treatment with Diaglipt in order to know the patient&#39;s baseline value. Liver function should be monitored during treatment with Diaglipt at three-month intervals during the first year and periodically thereafter. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of Diaglipt therapy is recommended.</p><p>Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Diaglipt. Following withdrawal of treatment with Diaglipt and LFT normalisation, treatment with Diaglipt should not be<br />reinitiated. Cardiac failure<br />A clinical trial of vildagliptin in patients with New York Heart Association (NYHA) functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre- existing congestive heart failure (CHF) versus placebo. Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive (see section 5.1).<br />There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients.<br />Skin disorders<br />Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non-clinical toxicology studies (see section 5.3). Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications. Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions. Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.<br />Acute pancreatitis<br />Use of vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.<br />If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.<br />Hypoglycaemia<br />Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p>Excipients<br />This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vildagliptin has a low potential for interactions with co -administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substanc es that are substrates, inhibitors or inducers of these enzymes.<br />4<br />Combination with pioglitazone, metformin and glyburide<br />Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions.<br />Digoxin (Pgp substrate), warfarin (CYP2C9 substrate)<br />Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions. However, this has not been established in the target population.<br />Combination with amlodipine, ramipril, valsartan or simvastatin<br />Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were obser ved after co-administration with vildagliptin.<br />Combination with ACE -inhibitors<br />There may be an increased risk of angioedema in patients concomitantly taking ACE -inhibitors. (See section 4.8).</p><p>As with other oral antidiabetic medicinal products the hypogl ycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of vildagliptin in pregnant women. Studies in animals have shown reproductive toxicity at high doses (see section 5.3). The potential risk for humans is unknown. Due to lack of human data, Diaglipt should not be used during pregnancy.<br />Breast-feeding<br />It is unknown whether vildagliptin is excreted in human milk. Animal studies have shown excretion of vildagliptin in milk. Diaglipt should not be used during breast-feeding.<br />Fertility<br />No studies on the effect on human fertility have been conducted for Diaglipt (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Safety data were obtained from a total of 3,784 patients exposed to vildagliptin at a daily dose of 50 mg (once daily) or 100 mg (50 mg twice daily or 100 mg once daily) in controlled trials of at least 12 weeks duration. Of these patients, 2,264 patients received vildagliptin as monotherapy and 1,520 patients received vildagliptin in combination with another medicinal product. 2,682 patients were treated with vildagliptin 100 mg daily (either 50 mg twice daily or 100 mg once daily) and 1,102 patients were treated with vildagliptin 50 mg once daily.<br />The majority of adverse reactions in these trials were mild and transient, not requiring treatment discontinuations. No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose.<br />Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to 24 weeks in duration, the incidence of ALT or AST elevations &ge; 3x ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg<br />5<br />twice daily and all comparators, respectively. These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.<br />Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an angiotensin converting enzyme inhibitor (ACE-Inhibitor). The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.</p><p>Tabulated list of adverse reactions<br />Adverse reactions reported in patients who received Diaglipt in double-blind studies as monotherapy and add- on therapies are listed below for each indication by system organ class and absolute frequency. Frequencies are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />Combination with metformin<br />Table 1 Adverse reactions reported in patients who received Diaglipt 100 mg daily in combination with metformin in double-blind studies (N=208)<br />Metabolism and nutrition disorders<br />Common<br />Hypoglycaemia<br />Nervous system disorders<br />Common<br />Tremor<br />Common<br />Headache<br />Common<br />Dizziness<br />Uncommon<br />Fatigue<br />Gastrointestinal disorders<br />Common<br />Nausea<br />Description of selected adverse reactions<br />In controlled clinical trials with the combination of vildagliptin 100 mg daily + metformin, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + metformin or the placebo + metformin treatment groups.<br />In clinical trials, the incidence of hypoglycaemia was common in patients receiving vildagliptin 100 mg daily in combination with metformin (1%) and uncommon in patients receiving placebo + metformin (0.4%). No severe hypoglycaemic events were reported in the vildagliptin arms.<br />In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was added to metformin (+0.2 kg and -1.0 kg for vildagliptin and placebo, respectively).<br />Clinical trials of up to more than 2 years&#39; duration did not show any additional safety signals or unforeseen risks when vildagliptin was added on to metformin.</p><p>Combination with a sulphonylurea<br />Table 2 Adverse reactions reported in patients who received Diaglipt 50 mg in combination with a sulphonylurea in double-blind studies (N=170)<br />Infections and infestations<br />Very rare<br />Nasopharyngitis<br />Metabolism and nutrition disorders<br />Common<br />Hypoglycaemia<br />Nervous system disorders<br />Common<br />Tremor<br />Common<br />Headache<br />Common<br />Dizziness<br />Common<br />Asthenia<br />Gastrointestinal disorders<br />Uncommon<br />Constipation<br />Description of selected adverse reactions<br />6<br />In controlled clinical trials with the combination of vildagliptin 50 mg + a sulphonylurea, the overall incidence of withdrawals due to adverse reactions was 0.6% in the vildagliptin 50 mg + sulphonylurea vs 0% in the placebo<br />+ sulphonylurea treatment group.<br />In clinical trials, the incidence of hypoglycaemia when vildagliptin 50 mg once daily was added to glimepiride was 1.2% versus 0.6% for placebo + glimepiride. No severe hypoglycaemic events were reported in the vildagliptin arms.<br />In clinical trials, weight did not change from baseline when vildagliptin 50 mg daily was added to glimepiride (-<br />0.1 kg and -0.4 kg for vildagliptin and placebo, respectively).</p><p>Combination with a thiazolidinedione<br />Table 3 Adverse reactions reported in patients who received Diaglipt 100 mg daily in combination with a thiazolidinedione in double-blind studies (N=158)<br />Metabolism and nutrition disorders<br />Common<br />Weight increase<br />Uncommon<br />Hypoglycaemia<br />Nervous system disorders<br />Uncommon<br />Headache<br />Uncommon<br />Asthenia<br />Vascular disorders<br />Common<br />Oedema peripheral<br />Description of selected adverse reactions<br />In controlled clinical trials with the combination of vildagliptin 100 mg daily+ a thiazolidinedione, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + thiazolidinedione or the placebo<br />+ thiazolidinedione treatment groups.<br />In clinical trials, the incidence of hypoglycaemia was uncommon in patients receiving vildagliptin + pioglitazone (0.6%) but common in patients receiving placebo + pioglitazone (1.9%). No severe hypoglycaemic events were reported in the vildagliptin arms.<br />In the pioglitazone add-on study, the absolute weight increases with placebo, Diaglipt 100 mg daily were 1.4 and 2.7 kg, respectively.<br />The incidence of peripheral oedema when vildagliptin 100 mg daily was added to a maximum dose of background pioglitazone (45 mg once daily) was 7.0%, compared to 2.5% for background pioglitazone alone.</p><p>Monotherapy<br />Table 4 Adverse reactions reported in patients who received Diaglipt 100 mg daily as monotherapy in double-blind studies (N=1,855)<br />Infections and infestations<br />Very rare<br />Upper respiratory tract infection<br />Very rare<br />Nasopharyngitis<br />Metabolism and nutrition disorders<br />Uncommon<br />Hypoglycaemia<br />Nervous system disorders<br />Common<br />Dizziness<br />Uncommon<br />Headache<br />Vascular disorders<br />Uncommon<br />Oedema peripheral<br />Gastrointestinal disorders<br />Uncommon<br />Constipation<br />Musculoskeletal and connective tissue disorders<br />Uncommon<br />Arthralgia<br />Description of selected adverse reactions<br />7<br />In addition, in controlled monotherapy trials with vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).</p><p>In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% (7 of 1,855) of patients treated with vildagliptin 100 mg daily compared to 0.2% (2 of 1,082) of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.<br />In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was administered as monotherapy (-0.3 kg and -1.3 kg for vildagliptin and placebo, respectively).<br />Clinical trials of up to 2 years&#39; duration did not show any additional safety signals or unforeseen risks with vildagliptin monotherapy.<br />Combination with metformin and a sulphonylurea<br />Table 5 Adverse reactions reported in patients who received Diaglipt 50 mg twice daily in combination with metformin and a sulphonylurea (N=157)<br />Metabolism and nutritional disorders<br />Common<br />Hypoglycaemia<br />Nervous system disorders<br />Common<br />Dizziness, tremor<br />Skin and subcutaneous tissue disorders<br />Common<br />Hyperhidrosis<br />General disorders and administration site conditions<br />Common<br />Asthenia<br />Description of selected adverse reactions<br />There were no withdrawals due to adverse reactions reported in the vildagliptin + metformin + glimepiride treatment group versus 0.6% in the placebo + metformin + glimepiride treatment group.<br />The incidence of hypoglycaemia was common in both treatment groups (5.1% for the vildagliptin + metformin<br />+ glimepiride group versus 1.9% for the placebo + metformin + glimepiride group). One severe hypoglycaemic event was reported in the vildagliptin group.<br />At the end of the study, effect on mean body weight was neutral (+0.6 kg in the vildagliptin group and -0.1 kg in the placebo group).</p><p>Combination with insulin<br />Table 6 Adverse reactions reported in patients who received Diaglipt 100 mg daily in combination with insulin (with or without metformin) in double-blind studies (N=371)<br />Metabolism and nutrition disorders<br />Common<br />Decreased blood glucose<br />Nervous system disorders<br />Common<br />Headache, chills<br />Gastrointestinal disorders<br />Common<br />Nausea, gastro-oesophageal reflux disease<br />Uncommon<br />Diarrhoea, flatulence<br />Description of selected adverse reactions<br />In controlled clinical trials using vildagliptin 50 mg twice daily in combination with insulin, with or without concomitant metformin, the overall incidence of withdrawals due to adverse reactions was 0.3% in the vildagliptin treatment group and there were no withdrawals in the placebo group.<br />The incidence of hypoglycaemia was similar in both treatment groups (14.0% in the vildagliptin group vs 16.4% in the placebo group). Two patients reported severe hypoglycaemic events in the vildagliptin group, and 6 patients in the placebo group.<br />At the end of the study, effect on mean body weight was neutral (+0.6 kg change from baseline in the vildagliptin group and no weight change in the placebo group).</p><p>Post-marketing experience<br />Table 7 Post-marketing adverse reactions<br />Gastrointestinal disorders<br />Not known Pancreatitis<br />Hepatobiliary disorders<br />Not known Hepatitis (reversible upon discontinuation of the medicinal product)<br />Abnormal liver function tests (reversible upon discontinuation of the medicinal product)<br />Musculoskeletal and connective tissue disorders<br />Not known Myalgia<br />Skin and subcutaneous tissue disorders<br />Not known Urticaria<br />Exfoliative and bullous skin lesions, including bullous pemphigoid<br />To Report any side effects:<br />Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC)<br />o SFDA call center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />Other GCC States:<br />- Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information regarding overdose with vildagliptin is limited.<br />Symptoms<br />Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy<br />subjects given Diaglipt for 10 days. At 400 mg, there were three cases of muscle pain, and individual cases of<br />mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, one subject<br />experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate<br />aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. Three other subjects experienced<br />oedema of the feet, with paraesthesia in two cases. All symptoms and laboratory abnormalities resolved<br />without treatment after discontinuation of the study medicinal product.<br />Management<br />In the event of an overdose, supportive management is recommended. Vildagliptin cannot be removed by<br />haemodialysis. However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code:<br />A10BH02<br />Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor.<br />Mechanism of action<br />The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in<br />increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide<br />1) and GIP (glucose-dependent insulinotropic polypeptide).<br />9<br />Pharmacodynamic effects<br />By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA- &beta; (Homeostasis Model Assessment&ndash;&beta;), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels.<br />By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.<br />The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.<br />The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.</p><p>Clinical efficacy and safety<br />More than 15,000 patients with type 2 diabetes participated in double-blind placebo- or active-controlled clinical trials of up to more than 2 years&#39; treatment duration. In these studies, vildagliptin was administered to more than 9,000 patients at daily doses of 50 mg once daily, 50 mg twice daily or 100 mg once daily. More than 5,000 male and more than 4,000 female patients received vildagliptin 50 mg once daily or 100 mg daily. More than 1,900 patients receiving vildagliptin 50 mg once daily or 100 mg daily were &ge; 65 years. In these trials, vildagliptin was administered as monotherapy in drug-na&iuml;ve patients with type 2 diabetes or in combination in patients not adequately controlled by other antidiabetic medicinal products.<br />Overall, vildagliptin improved glycaemic control when given as monotherapy or when used in combination with metformin, a sulphonylurea, and a thiazolidinedione, as measured by clinically relevant reductions in HbA1c from baseline at study endpoint (see Table 8).<br />In clinical trials, the magnitude of HbA1c reductions with vildagliptin was greater in patients with higher baseline HbA1c.<br />In a 52-week double-blind controlled trial, vildagliptin (50 mg twice daily) reduced baseline HbA1c by -1% compared to -1.6% for metformin (titrated to 2 g/day) statistical non-inferiority was not achieved. Patients treated with vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin.<br />In a 24-week double-blind controlled trial, vildagliptin (50 mg twice daily) was compared to rosiglitazone (8 mg once daily). Mean reductions were -1.20% with vildagliptin and -1.48% with rosiglitazone in patients with mean baseline HbA1c of 8.7%. Patients receiving rosiglitazone experienced a mean increase in weight (+1.6 kg) while those receiving vildagliptin experienced no weight gain (-0.3 kg). The incidence of peripheral oedema was lower in the vildagliptin group than in the rosiglitazone group (2.1% vs. 4.1% respectively).<br />In a clinical trial of 2 years&#39; duration, vildagliptin (50 mg twice daily) was compared to gliclazide (up to 320 mg/day). After two years, mean reduction in HbA1c was -0.5% for vildagliptin and -0.6% for gliclazide, from a mean baseline HBA1c of 8.6%. Statistical non-inferiority was not achieved. Vildagliptin was associated with fewer hypoglycaemic events (0.7%) than gliclazide (1.7%).<br />In a 24-week trial, vildagliptin (50 mg twice daily) was compared to pioglitazone (30 mg once daily) in patients inadequately controlled with metformin (mean daily dose: 2020 mg). Mean reductions from baseline HbA1c of 8.4% were -0.9% with vildagliptin added to metformin and -1.0% with pioglitazone added to metformin. A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving vildagliptin added to metformin.</p><p>In a clinical trial of 2 years&#39; duration, vildagliptin (50 mg twice daily) was compared to glimepiride (up to 6 mg/day &ndash; mean dose at 2 years: 4.6 mg) in patients treated with metformin (mean daily dose: 1894 mg). After 1 year mean reductions in HbA1c were -0.4% with vildagliptin added to metformin and -0.5% with glimepiride added to metformin, from a mean baseline HbA1c of 7.3%. Body weight change with vildagliptin was -0.2 kg vs<br />+1.6 kg with glimepiride. The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%). At study endpoint (2 years), the HbA1c was similar to baseline values in<br />both treatment groups and the body weight changes and hypoglycaemia differences were maintained.<br />In a 52-week trial, vildagliptin (50 mg twice daily) was compared to gliclazide (mean daily dose: 229.5 mg) in patients inadequately controlled with metformin (metformin dose at baseline 1928 mg/day). After 1 year, mean reductions in HbA1c were -0.81% with vildagliptin added to metformin (mean baseline HbA1c 8.4%) and -0.85% with gliclazide added to metformin (mean baseline HbA1c 8.5%); statistical non-inferiority was achieved (95%<br />10<br />CI -0.11 &ndash; 0.20). Body weight change with vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.<br />In a 24-week trial the efficacy of the fixed dose combination of vildagliptin and metformin (gradually titrated to a dose of 50 mg/500 mg twice daily or 50 mg/1000 mg twice daily) as initial therapy in drug-na&iuml;ve patients was evaluated. Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA1c by -1.82%, vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, metformin 1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA1c of 8.6%. The decrease in HbA1c observed in patients with a baseline &ge;10.0% was greater.</p><p>A 24-week, multi-centre, randomised, double-blind, placebo-controlled trial was conducted to evaluate the treatment effect of vildagliptin 50 mg once daily compared to placebo in 515 patients with type 2 diabetes and moderate renal impairment (N=294) or severe renal impairment (N=221). 68.8% and 80.5% of the patients with moderate and severe renal impairment respectively were treated with insulin (mean daily dose of 56 units and 51.6 units respectively) at baseline. In patients with moderate renal impairment vildagliptin significantly decreased HbA1c compared with placebo (difference of -0.53%) from a mean baseline of 7.9%. In patients with severe renal impairment, vildagliptin significantly decreased HbA1c compared with placebo (difference of - 0.56%) from a mean baseline of 7.7%.<br />A 24-week randomised, double-blind, placebo-controlled trial was conducted in 318 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with metformin (&ge;1500 mg daily) and glimepiride (&ge;4 mg daily). Vildagliptin in combination with metformin and glimepiride significantly decreased HbA1c compared with placebo.The placebo-adjusted mean reduction from a mean baseline HbA1c of 8.8% was<br />-0.76%.<br />A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without concomitant metformin (N=173). Vildagliptin in combination with insulin significantly decreased HbA1c compared with placebo. In the overall population, the placebo-adjusted mean reduction from a mean baseline HbA1c 8.8% was<br />-0.72%. In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively. The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the vildagliptin and placebo groups, respectively. Patients receiving vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).<br />In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA1c when vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%). The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs. 29.6%).</p><p>A 52-week multi-centre, randomised, double-blind trial was conducted in patients with type 2 diabetes and congestive heart failure (NYHA functional class I-III) to evaluate the effect of vildagliptin 50 mg twice daily (N=128) compared to placebo (N=126) on left-ventricular ejection fraction (LVEF). Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. Adjudicated cardiovascular events were balanced overall. There were more cardiac events in vildagliptin treated patients with NYHA class III heart failure compared to placebo. However, there were imbalances in baseline cardiovascular risk favouring placebo and the number of events was low, precluding firm conclusions. Vildagliptin significantly decreased HbA1c compared with placebo (difference of 0.6%) from a mean baseline of 7.8% at week 16. In the subgroup with NYHA class III, the decrease in HbA1c compared to placebo was lower (difference 0.3%) but this conclusion is limited by the small number of patients (n=44). The incidence of hypoglycaemia in the overall population was 4.7% and 5.6% in the vildagliptin and placebo groups, respectively.<br />Cardiovascular risk<br />A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration (mean exposure 50 weeks for vildagliptin and 49 weeks for comparators) was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators. The composite endpoint of adjudicated major adverse cardiovascular events (MACE) including acute myocardial infarction, stroke or cardiovascular death was similar for vildagliptin versus combined active and placebo comparators [Mantel&ndash; Haenszel risk ratio (M-H RR) 0.82 (95% CI 0.61-1.11)]. A MACE occurred in 83 out of 9,599 (0.86%) vildagliptin-treated patients and in 85 out of 7,102 (1.20%) comparator-treated patients. Assessment of each individual MACE component showed no increased risk (similar M-H RR). Confirmed heart failure (HF) events defined as HF requiring hospitalisation or new onset of HF were reported in 41 (0.43%) vildagliptin-treated patients and 32 (0.45%) comparator-treated patients with M-H RR 1.08 (95% CI 0.68-1.70).</p><p>Table 8 Key efficacy results of vildagliptin in placebo-controlled monotherapy trials and in add-on combination therapy trials (primary efficacy ITT population)<br />Monotherapy placebo-controlled studies<br />Mean baseline HbA1c (%)<br />Mean change from baseline in HbA1c (%) at week 24<br />Placebo-corrected mean change in HbA1c (%) at week 24 (95%CI)<br />Study 2301: Vildagliptin 50 mg twice daily (N=90)<br />8.6<br />-0.8<br />-0.5* (-0.8, -0.1)<br />Study 2384: Vildagliptin 50 mg twice daily (N=79)<br />8.4<br />-0.7<br />-0.7* (-1.1, -0.4)<br />*p&lt; 0.05 for comparison versus placebo<br />Add-on / Combination studies<br />Vildagliptin 50 mg twice daily + metformin (N=143)<br />8.4<br />-0.9<br />-1.1* (-1.4, -0.8)<br />Vildagliptin 50 mg daily + glimepiride (N=132)<br />8.5<br />-0.6<br />-0.6* (-0.9, -0.4)<br />Vildagliptin 50 mg twice daily + pioglitazone (N=136)<br />8.7<br />-1.0<br />-0.7* (-0.9, -0.4)<br />Vildagliptin 50 mg twice daily + metformin + glimepiride (N=152)<br />8.8<br />-1.0<br />-0.8* (-1.0, -0.5)<br />*p&lt; 0.05 for comparison versus placebo +comparator<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to 2.5 hours, but does not alter the overall exposure (AUC). Administration of vildagliptin with food resulted in a decreased Cmax (19%). However, the magnitude of change is not clinically significant, so that Diaglipt can be given with or without food. The absolute bioavailability is 85%.<br />Distribution<br />The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of vildagliptin at steady-state after intravenous administration (Vss) is 71 litres, suggesting extravascular distribution.<br />Biotransformation<br />Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. DPP-4 contributes partially to the hydrolysis of vildagliptin based on an in vivo study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent. Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. In vitro studies demonstrated that vildagliptin does not inhibit/induce CYP 450 enzymes. Therefore, vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.</p><p>Elimination<br />Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine<br />and 15% of the dose is recovered in the faeces. Renal excretion of the unchanged vildagliptin accounted for<br />23% of the dose after oral administration. After intravenous administration to healthy subjects, the total plasma<br />and renal clearances of vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after<br />intravenous administration is approximately 2 hours. The elimination half-life after oral administration is<br />approximately 3 hours.<br />Linearity/non-linearity<br />The Cmax for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in<br />an approximately dose proportional manner over the therapeutic dose range.<br />Characteristics in specific groups of patients<br />Gender<br />No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and<br />female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by vildagliptin<br />is not affected by gender.<br />Elderly<br />In healthy elderly subjects (&ge; 70 years), the overall exposure of vildagliptin (100 mg once daily) was increased<br />by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40<br />years). These changes are, however, not considered to be clinically relevant. DPP-4 inhibition by vildagliptin<br />is not affected by age.<br />Hepatic impairment<br />The effect of impaired hepatic function on the pharmacokinetics of vildagliptin was studied in patients with mild,<br />moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for<br />severe) in comparison with healthy subjects. The exposure to vildagliptin after a single dose in patients with<br />mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to<br />vildagliptin for patients with severe impairment was increased by 22%. The maximum change (increase or<br />decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant. There was<br />no correlation between the severity of the hepatic disease and changes in the exposure to vildagliptin.</p><p>Renal impairment<br />A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose<br />of vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment defined by<br />creatinine clearance (mild: 50 to &lt;80 ml/min, moderate: 30 to &lt;50 ml/min and severe: &lt;30 ml/min) compared<br />to normal healthy control subjects.<br />Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal<br />impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 and BQS867<br />increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment,<br />respectively. Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure<br />is similar to that in patients with severe renal impairment. LAY151 concentrations were approximately 2-3-fold<br />higher than in patients with severe renal impairment.<br />Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session<br />starting 4 hours post dose).<br />Ethnic group<br />Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7-fold human<br />exposure based on Cmax).<br />Accumulation of foamy alveolar macrophages in the lung was observed in rats and mice. The no-effect dose<br />in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human<br />exposure).<br />Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal<br />blood were observed in dogs. A no-effect level was not established.<br />Vildagliptin was not mutagenic in conventional in vitro and in vivo tests for genotoxicity.</p><p>A fertility and early embryonic development study in rats revealed no evidence of impaired fertility, reproductive<br />performance or early embryonic development due to vildagliptin. Embryo-foetal toxicity was evaluated in rats<br />and rabbits. An increased incidence of wavy ribs was observed in rats in association with reduced maternal<br />body weight parameters, with a no-effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased<br />foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of<br />severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-fold human exposure). A pre- and postnatal<br />development study was performed in rats. Findings were only observed in association with maternal toxicity at<br />&ge; 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.<br />A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/kg (approximately 200<br />times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to<br />vildagliptin were observed. Another two-year carcinogenicity study was conducted in mice at oral doses up to<br />1,000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed<br />with a no-effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure),<br />respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk<br />to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of<br />tumours only in one species and the high systemic exposure ratios at which tumours were observed.<br />In a 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses &ge; 5<br />mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At 5 mg/kg/day<br />(approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed. They<br />were reversible despite continued treatment and were not associated with histopathological abnormalities.<br />Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses<br />&ge; 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail<br />were observed at &ge; 80 mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day<br />during a 4-week recovery period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose, Lactose anhydrous, Sodium Starch Glycolate, and Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packages: 4 blisters (14 tablets / blister) are attached to a leaflet and inserted in an internal carton box.<br />available in packs containing 56 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>